Roche pays $75M for Simcere antibody SIM0660
Roche will pay Simcere Zaiming $75 million upfront for global rights to preclinical antibody SIM0660, in a deal potentially worth $1.53 billion.
Roche will pay Simcere Zaiming $75 million upfront for exclusive global rights to a preclinical trispecific antibody. The total potential value of the deal, including milestones and royalties, is $1.53 billion.
According to a release, the agreement covers the development, manufacturing, and commercialization of the asset, SIM0660. Simcere Zaiming is also eligible to receive tiered royalties of up to double digits on future net sales.
Deal Details and Strategic Rationale
Boris L. Zaïtra, Roche's head of corporate business development, stated the deal reflects the company's commitment to partnerships. "SIM0660 represents a potential advancement for patients with B-cell-mediated diseases," Zaïtra said in the release.
The asset is a key part of Roche's recent licensing activity. This agreement with Simcere marks Roche's second major deal in just over a week. On August 24, the company entered a separate pact with Hanmi Pharmaceutical for a clinical-stage urocortin-2 analog, involving a $190 million upfront payment and a total potential value of about $2.5 billion.
SIM0660's Mechanism and Potential
SIM0660 is designed to target three proteins: CD79a, CD19, and CD3. According to Simcere, the molecule combines a CD3-engaging arm that binds to T cells with domains targeting the B-cell antigens CD79a and CD19. This design aims to trigger T cell-mediated killing of target cells while limiting cytokine release.
The dual targeting of CD79a and CD19 could give the antibody therapeutic potential across various B-cell-mediated diseases. Simcere suggests it may work in patients who have previously been treated with CD20- or CD19-directed therapies. The company also sees potential for the antibody in treating B-cell-mediated autoimmune diseases.
Simcere's Licensing Track Record
Simcere Pharmaceutical Group has established its pipeline as a significant source of partnership revenue. The company reports it has now completed six out-licensing transactions with a potential aggregate value exceeding $6.1 billion.
Recent high-value deals from Simcere include the following:
| Partner | Asset | Stage | Deal Value |
|---|---|---|---|
| AbbVie | SIM0500 (trispecific T-cell engager) | Phase 1 | $1.05 billion |
| NextCure | SIM0505 (antibody-drug conjugate) | Phase 1 | $745 million |
| Ipsen | SIM0613 (ADC) | Preclinical | $1.06 billion |
| Boehringer Ingelheim | SIM0709 (bispecific for IBD) | Preclinical | 1.05 billion euros ($1.26 billion) |
Simcere Zaiming, the oncology-focused subsidiary involved in the Roche deal, was founded in 2023. Its parent company, Simcere Pharmaceutical Group, dates back to 1995. The Chinese biopharma previously partnered with G1 Therapeutics to commercialize the chemotherapy adjunct Cosela in China, Hong Kong, Macau, and Taiwan. It also markets the biliary tract cancer treatment Enweida in China.
Separately, Simcere spinout Simnova closed a nearly 400 million yuan Series B financing round on August 31. The cell therapy biotech, which spun out of Simcere in 2021, is advancing off-the-shelf CAR-NK and in vivo CAR-T programs.
